RESTORE-3 study demonstrates a 60.4% proptosis response rate versus 23.5% with placebo at Week 24, highlighting the potential ...

Roche’s vamikibart shows 1-year vision gains in Phase 3 uveitic macular edema trials, offering a non-steroid alternative; see ...

Merck ( MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, ...

Administering Keytruda via subcutaneous injection instead of an intravenous drip.In September 2026, such a drug was approved.

A new study shows that the dual EZH1/2 inhibitor valemetostat counteracts HTLV-1-induced epigenetic changes in retinal cells ...

Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...

It's Nobel Prize season and today we feature promising early results of a novel technique for treating blindness that made ...

Patients with blindness due to retinitis pigmentosa who received a treatment based on research that won the 2026 Nobel Prize in Physiology or Medicine had their ability to detect objects restored in a ...

Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met the primary endpoint in Chinese patients with inactive thyroid eye disease (TED), marking ...

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety ...

Innovent Biologics, Inc. announced that its independently developed recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME® (Teprotumumab N01 Injection, R&D code: IBI311), ...

Three people have received an innovative treatment designed to rejuvenate vision cells. In a presentation at the annual ...